RxDoctor Payments Data

Bernard Michlin, MD

Internal Medicine · San Diego, CANPI 1861492738

Payments from drug & device makers

$266,268in general payments, 2019–2025

Across 2,266 payments — averaging $117.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$122K
  • Lilly USA, LLC$61K
  • Sanofi-aventis U.S. LLC$47K
  • AstraZeneca$7K
  • Novo Nordisk$4K
  • AbbVie$3K
  • plus $23K from 54 others
$55,170in research payments, 2019–2025

Across 8 payments — averaging $6896.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Orexo US, Inc.$55K

What the payments were for

  • Consulting fees$10,8108%
  • Speaking & faculty fees$82,50460%
  • Travel & lodging$12,9389%
  • Food & beverage$31,66523%
  • Education$3820%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk AS520$122,076
Lilly USA, LLC252$60,612
Sanofi-aventis U.S. LLC93$46,604
AstraZeneca62$7,239
Novo Nordisk89$3,777
AbbVie(2 entities)175$2,584
Amgen(2 entities)84$1,685
UCB, Inc.80$1,548
Biohaven Pharmaceuticals, Inc.4$1,368
Vanda Pharmaceuticals Inc.49$1,292
Sunovion Pharmaceuticals Inc.77$1,198
Mannkind Corporation38$997
Teva Pharmaceuticals USA, Inc.31$863
Otsuka America Pharmaceutical, Inc.28$771
Novartis40$760
Neurelis, Inc.40$628
Neurocrine Biosciences, Inc.24$625
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)23$573
GSK26$558
Lundbeck LLC44$539
Takeda Pharmaceuticals U.S.A., Inc.30$520
Johnson & Johnson38$515
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC28$509
Pfizer34$503
Sanofi16$489
Bayer27$444
Indivior Inc.27$442
Sumitomo Pharma America, Inc.27$393
Nestle Healthcare Nutrition Inc.20$388
Axsome Therapeutics, Inc.8$383
Eisai Inc.21$380
Radius Health, Inc.17$360
Merz North America, Inc.3$340
Jazz Pharmaceuticals Inc.8$326
SK Life Science, Inc.13$305
Astellas Pharma US Inc16$273
Boehringer Ingelheim13$269
Boston Scientific3$248
Braeburn Inc.4$162
Merck8$160
Aimmune Therapeutics, Inc.8$152
Verity Pharmaceuticals Inc.5$149
Avanir Pharmaceuticals, Inc.8$133
Harmony Biosciences LLC4$132
Abbott6$129
Amarin Pharma, Inc.7$126
Daiichi Sankyo Inc.7$124
Soleno Therapeutics, Inc.6$118
Bausch Health US, LLC6$115
Sun Pharmaceutical Industries Inc.4$94
Orexo US, Inc.6$91
Acadia Pharmaceuticals Inc4$81
Exact Sciences3$72
Supernus Pharmaceuticals, Inc.3$68
E.r. Squibb & Sons, L.L.C.4$67
Mylan Specialty L.p.3$66
Arbor Pharmaceuticals, Inc.4$64
Xeris Pharmaceuticals, Inc.3$56
Ardelyx, Inc.2$55
Greenwich Biosciences, Inc.2$55

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$266,268 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$1,479,589
Medicare patients
862
Services billed
14,509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate68$369,677
OzempicSemaglutide306$351,134
FarxigaDapagliflozin Propanediol545$271,763
TrulicityDulaglutide239$261,164
Invega SustennaPaliperidone Palmitate75$231,726
EliquisApixaban408$171,326
LinzessLinaclotide263$142,959
JardianceEmpagliflozin212$105,853
ProliaDenosumab51$91,928
Evenity (2 Syringes)Romosozumab-Aqqg30$88,662
XareltoRivaroxaban229$85,619
FanaptIloperidone75$85,258
Dupixent PenDupilumab20$81,541
DapagliflozinDapagliflozin Propanediol234$74,505
RexultiBrexpiprazole47$61,050

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$3,777$398,447354 claims
Neurocrine Biosciences, Inc.Ingrezza$625$369,67768 claims
AstraZenecaFarxiga, Breztri Aerosphere, Lokelma$7,239$323,994616 claims
Lilly USA, LLCTrulicity, Mounjaro$60,612$321,564292 claims
Johnson & JohnsonInvega Sustenna, Xarelto$515$317,345304 claims
AbbVieLinzess, Vraylar$2,584$201,507307 claims
AmgenProlia, Evenity (2 Syringes)$1,685$180,59081 claims
PfizerEliquis$503$171,326408 claims
Boehringer IngelheimJardiance$269$105,853212 claims
Vanda Pharmaceuticals Inc.Fanapt$1,292$85,25875 claims
GSKTrelegy Ellipta, Breo Ellipta$558$84,678142 claims
Otsuka America Pharmaceutical, Inc.Rexulti$771$61,05047 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →